LOOP DIURETICS AND ANTIHYPERTENSIVE TREATMENT: FORGOTTEN PAST OR REAL PERSPECTIVE?


Cite item

Full Text

Abstract

Loop diuretics, especially torasemide, in treatment of arterial hypertension are discussed.

References

  1. Комитет экспертов РМОАГ / ВНОК. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
  2. Marik P.E., Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131: 1949 - 1962.
  3. Bennett N.M., Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am. J. Public Health. 1988; 78: 636 - 640.
  4. Кобалава Ж.Д., Гудков К.М. Гипертонические кризы: существуют ли реальные противоречия в классификации и лечении? Сердце. 2003; 2(3): 116 - 127.
  5. Колос И.П., Чазова И.Е., Терещенко С.Н., Наконечников С.Н. Риск сердечно-сосудистых осложнений у больных частыми гипертоническими кризами. Тер. арх. 2009; 9: 9 - 12.
  6. Wittner M., Di Stefano A., Wangemann P., Greger R. How do loop diuretics act? Drugs. 1991; (41 Suppl. 3): 1 - 13.
  7. Bhalla V., Hallows K.R. Mechanisms of ENaC regulation and clinical implications. J. Am. Soc. Nephrol. 2008; 19: 1845 - 1854.
  8. Rosario R.F., Wesson D.E. Primary hypertension and nephropathy. Curr. Opin. Nephrol. Hypertens. 2006; 15(2): 130 - 134.
  9. Kalaitzidis R., Li S., Wang C. et al. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am. J. Kidney Dis. 2009; 53 (4 Suppl. 4): S22 - S31.
  10. Чазова И.Е., Фомин В.В. Резистентная артериальная гипертензия. Тер. арх. 2008; 6: 80 - 85.
  11. Foster M.C., Hwang S.J., Larson M.G. et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am. J. Kidney Dis. 2008; 52(1): 39 - 48.
  12. Coresh J., Selvin E., Stevens L.A. et al. Prevalence of chronic kidney disease in the United States. J.A.M.A. 2007; 298(17): 2038 - 2047.
  13. Земченков А.Ю., Томилина Н.А. "К/ДОКИ" обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек). Нефрология и диализ 2004; 6(3): 204 - 220.
  14. Mann J.F., Gerstein H.C., Pogue J. et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern Med. 2001; 134(8): 629 - 636.
  15. Kostis J.B., Shelton B., Gosselin G. et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am. Heart J. 1996; 131(2): 350 - 355.
  16. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358(15): 1547 - 1559.
  17. Мухин Н.А., Фомин В.В., Моисеев С.В., Швецов М.Ю. Нефрогенная артериальная гипертензия: эволюция лечения. Тер. арх. 2005; 8: 70 - 78.
  18. Russo D., Gazzotti R.M., Testa A. Torasemide, a new loop diuretic, in patients with chronic renal failure. Nephron. 1990; 55(2): 141 - 145.
  19. Fliser D., Schröter M., Neubeck M. et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994; 46(2): 482 - 488.
  20. Gehr T.W., Rudy D.W., Matzke G.R. et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 1994; 56(1): 31 - 38.
  21. Vasavada N., Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003; 64(5): 1772 - 1779.
  22. Тареева И.Е., Кутырина И.М. Лечение нефрогенной гипертонии. Клин. мед. 1985; 6: 20 - 27.
  23. Risler T., Schwab A., Kramer B. et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology. 1994; 84 (Suppl. 2): 155 - 161.
  24. Goodfriend T.L., Ball D.L., Oelkers W., Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998; 63(3): PL45-PL50.
  25. Struthers A.D. Impact of aldosterone on vascular pathophysiology. Congest. Heart Fail. 2002; 8: 18 - 22.
  26. Franse L.V., Pahor M., Di Bari M. et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000; 35: 1025 - 1030.
  27. López B., González A., Hermida N. et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int. Suppl. 2008; (111): S19-S23.
  28. López B., González A., Beaumont J. et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007; 50(9): 859 - 867.
  29. Mosso L., Carvajal C., Gonzales A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161 - 165.
  30. Rossi G.P., Bernini G., Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 2006; 48(11): 2293 - 2300.
  31. Vasan R.S., Evans J.C., Larson M.G. et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004; 351: 33 - 42.
  32. Born-Frontsberg E., Reincke M., Rump L.C. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J. Clin. Endocrinol. Metab. 2009; 94(4): 1125 - 1130.
  33. Berecek K.H., Farag A., Bahtiyar G. et al.Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr. Hypertens. Rep. 2004; 6(3): 211 - 212.
  34. Chapman N., Dobson J., Wilson S. et al. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension. 2007; 49: 839 - 845.
  35. Mantero F., Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann. Endocrinol (Paris). 2000; 61(1): 52 - 60.
  36. Handler J. Maximizing diuretic therapy in resistant hypertension. J. Clin. Hypertens. (Greenwich). 2007; 9(10): 802 - 806.
  37. Lyseng-Williamson K.A. Torasemide prolonged release. Drugs. 2009; 69(10):1363 - 1372.
  38. Roca-Cusachs A., Aracil-Vilar J., Calvo-Gómez C. et al. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc. Ther. 2008; 26(2): 91 - 100.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies